CN105663944A

CN105663944A - Medicine combination for treating lung cancer

Info

Publication number: CN105663944A
Application number: CN201610044050.9A
Authority: CN
Inventors: 高淑萍
Original assignee: Individual
Current assignee: Individual
Priority date: 2016-01-22
Filing date: 2016-01-22
Publication date: 2016-06-15

Abstract

The invention discloses a medicine combination for treating lung cancer.The medicine combination comprises Radix astragali, Radix adenophorae, Radix stemona, lily, Ganoderma lucidum, Bletilla striata, Poria cocos, Radix scutellariae, Folium mori, jujube leaf, bamboo leaf, Herba houttuyniae and fried Fructus oryzae germinatus.The traditional Chinese medicine combination is based on dialectical therapy theory of traditional Chinese medicine, the objectives of clearing lung qi and lowering lung fire are achieved by strengthening body resistance to eliminate pathogenic factors, activating blood to remove stasis, clearing heat for detoxification and softening hard lumps to dissipate stagnation, and the medicine combination performs symptomatic treatment and has good treatment effect on the lung cancer clinically.

Description

A kind of pharmaceutical composition treating lung cancer

Technical field

The invention belongs to medical art, it is specifically related to a kind of medicine treating lung cancer.

Background technology

Lung cancer has another name called lung bronchogenic carcinoma, originates from lung mucous membrane, is the common malignant tumour of lung. Lung cancer belongs to the category of " lung amasss " in traditional Chinese medicine, " ruffian addiction ", " hemoptysis ", " pectoralgia ". Some situations of this disease relevant, in the medical book in the remaining successive dynasties that sporadically appear. As " Plain Questions. strange sick opinion " say " sick fullness in the hypochondrium, the circulation of vital energy in the wrong direction ... .. name of disease breath is long-pending, and this might as well in food. " specify this disease position under the side of body, taking the circulation of vital energy in the wrong direction as main symptom, and do not hinder diet. Symptom described herein is when belonging to initial stage symptom. " spirit pivot. the sick shape section of perverse trend internal organs " record: " lung arteries and veins ... sliding Sheng is gas on beautifully adorned breath ", " the micro-urgency of lung arteries and veins is lung cold heat, and idle, hemoptysis, draws lumbago and backache. " disease at this moment develops into mid-term, has had obvious clinical manifestation. And " spirit pivot. the beautiful very dirty opinion of machine " " gas is full in the heart, inconvenience of panting, and interior pain draws shoulder neck, the de-meat of body heat " recorded, it appears that lung cancer has developed into late period.

Motherland's medical science is thought, the generation of lung cancer, always falls ill because of empty, and because of void so that reality, void be this, real in marking, and void is general, and reality is locality. With regard to empty, patients with lung cancer mainly insufficiency of lung-QI, deficiency of lung-YIN be main, spleen-deficiency, suffer from a deficiency of the kidney, asthenia of qi and blood holds concurrently and visible; With regard to reality, patients with lung cancer then based on the stagnation of the circulation of vital energy, the blood stasis of blood, phlegm is solidifying, the poly-fire of dampness, poison is prosperous, when debating it in detail during treatment.

Summary of the invention

The object of the invention is to provide the pharmaceutical composition of the treatment lung cancer that a kind of curative effect is definite, security is high.

Technical scheme provided by the invention is: a kind of pharmaceutical composition treating lung cancer, it is characterized in that, it is mainly made up of the raw material of following weight part: Radix Astragali 25-35 weight part, the root of straight ladybell 10-20 weight part, tuber of stemona 5-15 weight part, lily 15-25 weight part, glossy ganoderma 15-25 weight part, bletilla striata 5-15 weight part, Poria cocos 10-20 weight part, root of large-flowered skullcap 5-15 weight part, mulberry leaf 15-25 weight part, jujube leaf 15-25 weight part, leaf of bamboo 5-15 weight part, Radix Glycyrrhizae 3-6 weight part, donkey-hide gelatin 5-15 weight part, turtle shell 5-15 weight part, Herba Scutellariae Barbatae 15-25 weight part, Herba Houttuyniae 15-25 weight part, Herba Agrimoniae 10-20 weight part, fry rice bud 25-35 weight part, sweet fennel 15-25 weight part.

Preferably, the pharmaceutical composition for the treatment of lung cancer, the amount ratio of its bulk drug is: the Radix Astragali 30 weight part, the root of straight ladybell 15 weight part, the tuber of stemona 10 weight part, lily 20 weight part, glossy ganoderma 20 weight part, the bletilla striata 10 weight part, Poria cocos 15 weight part, the root of large-flowered skullcap 10 weight part, mulberry leaf 20 weight part, jujube leaf 20 weight part, the leaf of bamboo 10 weight part, Radix Glycyrrhizae 3-6 weight part, donkey-hide gelatin 10 weight part, turtle shell 10 weight part, Herba Scutellariae Barbatae 20 weight part, Herba Houttuyniae 20 weight part, Herba Agrimoniae 15 weight part, fry rice bud 30 weight part, sweet fennel 20 weight part.

Preferably, the pharmaceutical composition treating lung cancer is oral preparation or external application agent. Described oral preparation is decoction, pill, capsule. Described external application agent comprises washout formulation or bubble pin agent.

Preferably, described lung cancer comprises small cell lung cancer, squama cancer, gland cancer, bronchioalveolar carcinoma, undifferentiated carcinoma.

Another object of the present invention is to the purposes providing a kind of foregoing pharmaceutical composition for the preparation for the treatment of lung-cancer medicament.

The Chinese medicine medicine of the present invention can adopt the ordinary method of Chinese medicine preparation to be prepared from oral medicine, such as oral decoction; Can also be pill, capsule, tablets and other formulations. Preparation method comprises and being decocted by these material medicines together water, is prepared into oral liquid; Or liquid concentration extracting effective components can be made pill, capsule, tablet etc. But these all can not limit the scope of the invention.

The Chinese medicine medicine advantage of the present invention is: the pharmaceutical composition of the present invention treats based on theory by differential diagnosis in tcm,, heat-clearing detumescence, softening and resolving hard mass promoting blood circulation and removing blood stasis by strengthening vital QI to eliminate pathogenic factors, fall the gasification stasis of blood, clearing lung-heat gas and fall lung-fire, improve for the purpose of immunity function to reach to draw out pus by applying a plaster to the affected part to consolidate, various lung cancer is all had good efficacy.

In addition, the pharmaceutical preparation of the present invention is simple, it may also be useful to convenient, natural environmental-protective, has good economic benefit and social benefit.

Embodiment

Below in conjunction with specific embodiment, such scheme is described further. It will be understood that these embodiments are not limited to for illustration of the present invention limit the scope of the invention. The implementation condition adopted in embodiment can do further adjustment according to the condition of concrete producer, and unreceipted implementation condition is generally the condition in normal experiment.

One, embodiment 1

Take agents component respectively: the Radix Astragali 30 weight part, the root of straight ladybell 15 weight part, the tuber of stemona 10 weight part, lily 20 weight part, glossy ganoderma 20 weight part, the bletilla striata 10 weight part, Poria cocos 15 weight part, the root of large-flowered skullcap 10 weight part, mulberry leaf 20 weight part, jujube leaf 20 weight part, the leaf of bamboo 10 weight part, Radix Glycyrrhizae 3-6 weight part, donkey-hide gelatin 10 weight part, turtle shell 10 weight part, Herba Scutellariae Barbatae 20 weight part, Herba Houttuyniae 20 weight part, Herba Agrimoniae 15 weight part, fries rice bud 30 weight part, sweet fennel 20 weight part; First medicine is added before boiling medicine cold water and soaks 1 hours, be conducive to the precipitation of effective ingredient. Boil medicine the most handy marmite, it is possible to use metal vessel. The medicine chopsticks floated over after adding water on the water surface stir up and down, Chinese medicine is soaked in water completely, the water surface to be exceeded Chinese medicine 2-3cm, boiling medicine after generally first boiling with big fire, then boil with slow fire, general every agent should decoct three times, the first time fried time is for boiling latter 30 minutes, second time minable water yield relatively should lack by first time, and the fried time, third time was with second time in order to boil latter 40 minutes. Respectively take concoction for three times 150-200 milliliter, for subsequent use after mixing.

Two, animal experiment

In order to evaluate the pharmacologic effect of Chinese medicine medicine of the present invention, contriver entrusts Suzhou Medical College that Chinese medicine medicine of the present invention has been carried out animal experiment

Kunming mice, BALB/C mice: breed by Suzhou Medical College Experimental Animal Center and provide.

Experimental technique:

Imitative clinical application method, by the medicine of the preparation in embodiment 1 (according to kilogram/body weight calculates, the 2-4 being about equivalent to people's usual amounts is doubly) in 24 hours, every mouse gastric infusion amount is 1ml/10g body weight, observe 7 days continuously after administration, mouse activity, feed, breathing and stool and urine etc. have no significant change, also have no mouse and have the phenomena of mortality, after experiment terminates, part mouse becomes celestial through putting to death and finds that minority mouse liver has slight enlargement, in slight cavity sample sex change under microscope, other main organs changes there are no obvious pathologic.

Embodiment 2

Hemolysin test is with reference to " middle pharmacological experimental methodology " (Science and Technology of Shanghai press, 1991) of Li Yikui chief editor

Body weight is selected to be the healthy mice of 18-22g, male and female half and half, it is divided at random 4 groups (seeing the following form), every abdominal injection 5% chicken red blood corpuscle 0.2mL carries out immunity, and connect following table administration 3 days simultaneously, the 4th day blood sampling separation of serum after immunity, with getting dilute serum 1mL and 5% chicken red blood corpuscle suspension 0.5mL after normal saline dilution 100 times, 10% complement 0.5mL mixes, 30 seconds are acted in 37 DEG C of water-baths, stopped reaction in 0 DEG C of refrigerator, centrifuging and taking supernatant liquor is in 540nm place colorimetric estimation optical density(OD) (OD) of 721 spectrophotometers, and establish the blank of not increase serum, get when its supernatant liquor is cooked colorimetric and adjust 0 benchmark, result is as follows: table 1

The above results illustrates that medicine of the present invention significantly increases mice serum hemolysin.

Embodiment 2

Lymphocyte transformation is tested--with reference to " middle pharmacological experimental methodology " (Science and Technology of Shanghai press, 1991) of Li Yikui chief editor

Selection body weight is the healthy kunming mice of 18-22g, and male and female half and half, are divided into 4 groups (seeing the following form) at random, every intramuscular injection 10mg/kg, totally three days. In injection the day before yesterday by following table grouping administration, every day gavage once, totally 7 days, tail vein blood smear behind after last administration 24 hours, the dyeing of end clan, the percentage of lymphoblast and transition cell in counted under microscope 100 lymphocytes, result is as follows:

Table 2

Compared with physiological saline group, * P < 0.05, * * P < 0.01

The above results shows that the conversion reaction that medicine of the present invention can make mouse be stimulated by PHA strengthens, and can improve the responsibility of T lymphocyte, can improve the immunologic function of mouse.

Embodiment 3

Medicine is on the impact of peritoneal macrophage function--with reference to " middle pharmacological experimental methodology " (Science and Technology of Shanghai press, 1991) of Li Yikui chief editor

Selection body weight is the healthy kunming mice of 18-22g, male and female half and half, it is divided at random 4 groups (seeing the following form), respectively by following table grouping administration, every day gavage once, continuous 15 days, after last administration 24 hours, every mouse abdominal injection lemon yellow staphylococcus suspension 0.5ml (100cfu/ml), put to death mouse, immediately intraperitoneal injection of saline 2ml with cervical vertebra dislocation method after 1 hour, and massage mouse web portion, drawing 0.5ml abdominal cavity drop sheet, Giemsa stain, basis of microscopic observation result is as follows:

Table 3

Compared with physiological saline group, * P < 0.05, * * P < 0.01

The above results shows that medicine of the present invention can significantly improve mouse macrophage percentage and phagocytic index.

Embodiment 5

Measure mice serum IgG levels

Tested serum, through, after doubling dilution, being quantitatively added on the agar slide of preparation, carries out two immunodiffusion with IgG antibody, and its result is as follows:

Table 4

Test-results shows: medicine small dose group of the present invention can improve mouse IgG value.

T* value is each group of comparative figure with negative control.

Embodiment 6

Hemolysin IgM measures

Selecting body weight to be the BALB/C mice of 18-22g, male and female half and half, are divided into 6 groups (seeing the following form) at random, and respectively by following table grouping two weeks, at the 10th day of administration, every mouse abdominal injection 5% chicken red blood corpuscle 0.2ml carried out immunity. Immunity gets blood on the 4th day, separation of serum, after normal saline dilution 100 times, get the rear serum 1mL and 5% chicken red blood corpuscle suspension 0.5ml of dilution, 10% complement 0.5mL is blended in 37 DEG C of effect 30s, and 0 DEG C of refrigerator stopped reaction, gets supernatant liquor after centrifugal, in 721 spectrophotometer 540nm place colorimetrics, measure optical density(OD) (OD value).And with the blank of increase serum, get when its supernatant liquor is cooked colorimetric and adjust 0 benchmark, result is as follows:

Table 5

The above results shows, and the above results shows that medicine of the present invention can obviously increase mice serum hemolysin IgM content, illustrates that medicine of the present invention can improve the function of mouse humoral immune.

Embodiment 7

Selecting body weight 18-22g mice with tumor (Chinese Academy of Sciences's Shanghai Experimental Animal Center), knurl kind lewis cell is that Chinese Academy of Sciences's Shanghai Experimental Animal Center goes down to posterity. It is set to experimental group and comparison placebo. With embodiment 1 medicine (concentration is 2g/mL), dosage is 5g/kg, continuous 10 days of oral administration. Result is as follows: table 6

According to above result, the anti-lung-cancer medicament of oral the present invention, can obviously extend the survival time of lung cancer in mice, through statistical treatment, P value < 0.05, there is significant difference.

Above-mentioned example, only for the technical conceive of the present invention and feature are described, its object is to allow person skilled in the art can understand the content of the present invention and implement according to this, can not limit the scope of the invention with this. All equivalent transformations of doing according to spirit of the invention or modification, all should be encompassed within protection scope of the present invention.

Claims

1. treat the pharmaceutical composition of lung cancer for one kind, it is characterized in that, it is mainly made up of the raw material of following weight part: Radix Astragali 25-35 weight part, the root of straight ladybell 10-20 weight part, tuber of stemona 5-15 weight part, lily 15-25 weight part, glossy ganoderma 15-25 weight part, bletilla striata 5-15 weight part, Poria cocos 10-20 weight part, root of large-flowered skullcap 5-15 weight part, mulberry leaf 15-25 weight part, jujube leaf 15-25 weight part, leaf of bamboo 5-15 weight part, Radix Glycyrrhizae 3-6 weight part, donkey-hide gelatin 5-15 weight part, turtle shell 5-15 weight part, Herba Scutellariae Barbatae 15-25 weight part, Herba Houttuyniae 15-25 weight part, Herba Agrimoniae 10-20 weight part, fry rice bud 25-35 weight part, sweet fennel 15-25 weight part.

2. the pharmaceutical composition for the treatment of lung cancer according to claim 1, it is characterised in that, the amount ratio of its bulk drug is: the Radix Astragali 30 weight part, the root of straight ladybell 15 weight part, the tuber of stemona 10 weight part, lily 20 weight part, glossy ganoderma 20 weight part, the bletilla striata 10 weight part, Poria cocos 15 weight part, the root of large-flowered skullcap 10 weight part, mulberry leaf 20 weight part, jujube leaf 20 weight part, the leaf of bamboo 10 weight part, Radix Glycyrrhizae 3-6 weight part, donkey-hide gelatin 10 weight part, turtle shell 10 weight part, Herba Scutellariae Barbatae 20 weight part, Herba Houttuyniae 20 weight part, Herba Agrimoniae 15 weight part, fry rice bud 30 weight part, sweet fennel 20 weight part.

3. the pharmaceutical composition for the treatment of lung cancer according to claim 1, it is characterised in that, the medicine for the treatment of lung cancer is oral preparation or external application agent.

4. the pharmaceutical composition for the treatment of lung cancer according to claim 3, it is characterised in that, described oral preparation is decoction, pill, capsule.

5. the pharmaceutical composition for the treatment of lung cancer according to claim 1, it is characterised in that, described lung cancer comprises small cell lung cancer, squama cancer, gland cancer, bronchioalveolar carcinoma, undifferentiated carcinoma.

6. pharmaceutical composition described in the arbitrary item of claim 1-5 is for the preparation of the application of the medicine for the treatment of lung cancer.

7. purposes according to claim 6, it is characterised in that, described lung cancer comprises small cell lung cancer, squama cancer, gland cancer, bronchioalveolar carcinoma, undifferentiated carcinoma.